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A B S T R A C T
Serum proteins and immunoglobulin (Ig) findings in 119 non-Hodgkin’s lymphoma (NHL) patients were analysed.
Out of them 96 (81%) patients had B non-Hodgkin lymphoma (B-NHL), and 23 (19%) T-NHL. Indolent type of NHL was
more frequent (77 patients, 65%), then aggressive type of NHL (42 patients, 35%). Most patients had normal serum pro-
tein concentration, the increased protein concentration was seen in 17% of patients while decreased concentration was
noticed in 7% of patients. Hypoalbuminaemia was more frequent (43%) then hyperalbuminaemia (1%). In contrast to al-
bumin, low levels of other protein fractions (alpha1-, alpha2-, and beta-globulin) were rather rare (0.6%, 4%, and 3% of
patients, respectively) and high levels were frequent (23%, 37%, and 8%, respectively). Polyclonal hyperimmunoglobu-
linaemia was more frequent finding than hypoimmunoglobulinaemia. In 29% patients higher IgG level and in 25% pa-
tients higher IgA level were found. IgM hypoimmunoglobulinaemia (22%) was more frequent than IgG (11%) and IgA
(8%) hypoimmunoglobulinaemia. M-spike in serum protein electrophoresis was found in 11 (7%) patients. The statisti-
cally significant association was not found between serum Ig concentration and lymphoma malignancy grade as well as
between serum Ig concentration and immunologic origin of lymphoma. T-NHL patients have more often IgA concentra-
tion level above or under normal values than B-NHL patients (p<0.05).
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Introduction
Non-Hodgkin’s lymphomas (NHL) are tumours of the
immune system causing very often the alteration of im-
mune function in affected patients which is not surpris-
ing because one function of the immune system is the
production and secretion of immunoglobulin molecules.
Immunoglobulin production depends on normal B- and
T-cell interactions and may be estimated by measuring
serum immunoglobulin levels1. Although there are evi-
dence that altered immunity is a risk factor for develop-
ment of non-Hodgkin lymphoma, the analysis of immune
function after the diagnosis of NHL do not show the im-
munological conditions before the development of lym-
phoma2. The papers with laboratory findings in patients
with NHL are rather scarce. Although there are some
studies dealing with this problem it is hard to compare
data from these studies because some old classifications
of NHL were used3.
The aim of the present study was to analyze serum
immunoglobulin levels in NHL patients in order to find
out whether certain histological types could be charac-
terised by the particular immmunoglobulin profile.
Patients and Methods
In retrospective study from 5 years period serum im-
munoglobulin levels were analysed in 119 consecutive
untreated adult patients with NHL in Department of
Medicine, »Merkur« University Hospital in Zagreb, Croa-
tia. Diagnosis of NHL was established immunohisto-
logically on samples of lymph node, spleen, or other tis-
sues. Patient with haematological criteria for acute lym-
phatic or chronic lymphocytic leukaemia were excluded
from this study.
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According to the WHO classification4 all patients were
grouped as indolent or aggressive type, and according to
lymphoma cells origin in T- and B-NHL groups, respec-
tively. Serum protein electrophoresis was performed on
acetate cellulose Cellogen, Chemtron. For immunoglobu-
lin quantitation radial immunodiffusion method with
Tri-Partigen plates Behringwerke and heterologous anti-
human immunoglobulin antisera were used. Serum im-
munoglobulin findings at diagnosis were compared among
different histologic and immunologic groups. Null hy-
pothesis was tested (at alpha=0.05) using the c2 for fre-
quency tables, one-way analysis of variance and Krus-
kal-Wallis rank test.
Results
Clinical and morphologic characteristics of NHL pa-
tients are shown in Table 1. Out of 119 patients in 96
(81%) patients B-NHL was diagnosed, and in 23 (19%)
T-NHL. Indolent type of NHL was more frequent (77 pa-
tients, 65%), then aggressive type of NHL (42 patients,
35%). Median age was 56 years, range 15 to 88 years.
Male to female ratio was 1.6:1.
Summarized laboratory findings of all our patients
are presented in Table 2. Although median of serum pro-
tein and immunoglobulin levels are in normal range,
some patients had extremely low or high value of these
parameters.
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TABLE 1
NON-HODGKIN’S LYMPHOMA PATIENTS’ CHARACTERISTICS
Age Median 56 y
Range 15–88 y
Sex Men 74 (62%)
Women 45 (38%)
M:F 1.6:1
Histology (grade of malignancy) Indolent 77 (65%)
Aggressive 42 (35%)
Immunological type T-NHL 23 (19%)
TABLE 2
SERUM PROTEINS AND IMMUNOGLOBULINS IN NHL PATIENTS AT DIAGNOSIS (N=119)
Variables X SD Min Max Med Normal values
Totpr (g/L) 70.8 9.27 45 108 71 64–82
Alb (g/L) 30.09 5.87 19.2 50.1 39.4 36–52
a1 (g/L) 2.91 0.89 1.2 6.7 2.7 1.5–3.5
a2 (g/L) 6.98 2.11 1.9 14.8 6.6 4.1–7.3
b (g/L) 7.72 1.42 3.9 13.1 7.9 5.8–9.6
g (g/L) 15.05 7.16 5.5 57.6 13.3 10.0–15.7
IgG (g/L) 16.46 8.77 1.2 60 14.3 10.0–17.0
IgA (g/L) 2.83 2.99 0.1 31.1 2.4 0.8–3.0
IgM (g/l) 1.32 0.93 0.2 5.8 1 0.7–2.4
X – mean value, SD – standard deviation, Max – maximum value, Min – minimum value, Med – median, Totpr – total serum protein,
Alb – albumin, a1 – alpha1-a2 – alpha2b– beta-globulin, g – gama-IgG – immunoglobulin G, IgA – immunoglobulin A, IgM – immuno-
globulin M
TOTAL PROTEIN CONCENTRATION (g/L)
17%
74%
9%
< 63 N > 83
ALBUMINS (g/L)
43%
56%
1%
< 37 N > 53
a1-GLOBULINS (g/L)
1%
76%
23%
< 1.4 N > 3.6
a2-GLOBULINS (g/L)
4%
57%
37%
< 4 N > 7.4
b-GLOBULINS (g/L)
8%
84%
8%
< 5.8 N > 9.7
TABLE 3
PATIENTS DISTRIBUTION ACCORDING TO TOTAL PROTEIN,
ALPHA1-, ALPHA2-, AND BETA2-GLOBULIN CONCENTRATION
Distribution of patients with aberrant findings of se-
rum proteins, immunoglobulin G, A, and M is presented
as percentage of all patients with NHL (Table 3). Most
patients had normal concentrations of the measured pa-
rameters. Hypoproteinaemia was found in 17% patients,
and hyperproteinaemia in 9% patients. Hypoalbuminae-
mia was more frequent (43%) than hyperalbuminaemia
(1%). Contrary to albumins, low serum concentrations of
alpha1-globulin, alpha2-globulins, and beta-globulin fra-
ction were found in 0.6%, 4%, and 3% of patients, respec-
tively. High serum concentrations of alpha1-, alpha2-,
and beta-globulin fractions were more frequent (23%,
37%, and 8%, respectively) in our NHL patients.
Hypogammaglobulinaemia was found in 15%, and
hypergammaglobulinaemia in 30% NHL patients at di-
agnosis (Table 3). In contrast to IgM with higher fre-
quency of patients with hypogammaglobulinaemia (22%),
the frequency of patients with hyperglobulinaemia of
IgG, and IgA was higher (29% and 25%, respecitvely)
then the frequency of patients with hypogammaglobuli-
naemia (11% and 8%, respectively) (Table 4). »M«-spike
in serum protein electrophoresis was found in 11 (7%)
patients with NHL. High levels of immunoglobulin G
and A were found in 29% and 25% patients, respectively.
Hypoimmunoglobulinaemia was found to be more fre-
quent in class IgM than in class IgG and class IgA (22%,
11% and 8% respectively) (Table 4). Highly significant
correlation between gammaglobulins and IgG concentra-
tion was found (r=0.85, p<0.00001).
The statistical significance of the association between
serum immunoglobulin concentration and histological
and immunological findings was analysed with Krus-
kal-Wallis test. Statistically significant association was
found between prognostic groups of histology and al-
tered, total serum protein findings, albumins, as well as
alpha2-globulins. Aggressive NHL patients had lower
concentrations of serum proteins (p=0.05), albumins
(p<0.01), as well as higher concentrations of serum
alpha2-globulins (p<0.05) than indolent NHL patients
(Table 5). Statistically significant association was found
between immunology of lymphoma, serum alpha2-globu-
lins, and immunoglobulin A. B-NHL patients have sig-
nificantly more often aberration in serum concentration
of immunoglobulin A than T-NHL patients (p<0.05). On
the other side T-NHL patients have more often higher
concentrations of alpha2-globulins (p<0.05) (Table 5).
Significant association between malignancy type NHL
and the concentration of any immunoglobulin were not
established. The same was true when immunological
finding of lymphoma was correlated with the concentra-
tion of total serum proteins, albumins, alpha1-globulins,
beta-globulins, gamma-globulins, immunoglobulin G, and
immunoglobulin M.
Discussion
Laboratory findings of serum proteins are variable
and nonspecific for NHL. In our study hypoalbuminae-
mia was the most frequent aberration in serum protein
findings, followed by increased serum alpha2-globulin
level, hypergammaglobulinaemia and increased serum
alpha1-globulin level. Only sporadic cases of nephritic
syndrome associated with lymphoma disease were pub-
lisher. Higher alpha2-globulin serum concentration is rel-
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TABLE 4
PATIENTS DISTRIBUTION ACCORDING TO SERUM
GAMMA-GLOBULINS AND IMMUNOGLOBULIN G, A AND M
TABLE 5
ASSOCIATION OF SERUM PROTEIN FINDINGS AND SERUM IMMUNOGLOBULINS WITH HISTOLOGICAL AND IMMUNOLOGICAL FIND-
INGS OF LYMPH NODES IN NHL PATIENTS
Variable
Prognostic group
– histological type of lymphoma
Prognostic group
– immunological origin of lymphoma
Total proteins Aggressive-NHL – lower serum protein concentration
p=0.05
NS
Albumins Aggressive-NHL – lower serum albumins
p<0.01
NS
atively frequent finding (37%) in our patients while in
the other authors’ studies in well differentiated lym-
phocytic lymphoma only 25% patients have the same
findings5. Measurement of serum albumin concentration
has been proven relevant in assessing prognosis in an-
other lymphoproliferative entity – multiple myeloma. Se-
rum albumin concentration has been included in the re-
cently published and widely used International Staging
System (ISS) prognostic classification in multiple my-
eloma6. This significance of serum albumin as prognostic
factor in multiple myeloma is connected with possible re-
nal demage and consequent low level of serum albumin
concentration.
The alterations of cellular and/or humoral immunity
in NHL patients are not uncommon7–15. In NHL patients
intrinsic B-cell defects, increased T-cell or monocyte sup-
pressor activity, and diminished T-helper activity may
also contribute to the hypogammaglobulinaemia9,16–19.
Hypogammaglobulinaemia was seen in 5% of patients
with well differentiated lymphocytic lymphoma and in
45% patients with chronic lymphocytic leukaemia11. The
hypogammaglobulinaemia that occurs in lymphoproli-
ferative disorders is generally mild and is usually seen in
the terminal stage, when massive neoplastic infiltration
of bone marrow and lymphatic tissues develops7,8,16,20–22.
M-spike in serum protein electrophoresis is not a fre-
quent finding except in solid organ transplant patients
with post-transplant lymphoproliferative disorder3,23–25.
In our investigation M-spike was found in 7% of NHL pa-
tients that is higher than expected in Caucasian general
population 50 yeas of age or older26. In some subsets of
NHL, the monoclonal gammapathy was detected more
frequently than in our study27,28.
In our study the most frequent hypoimmunoglobu-
linaemia is in class IgM (22%), followed by class IgG
(11%) and IgA (8%). Two recent reports showed than
IgM and IgA were also decreased in patients with NHL10,14.
IgG levels were not decreased in one study10, but de-
creased in the others14,24. Low serum IgG level (<10g/L),
low total immunoglobulins on presentation were signifi-
cantly associated with short survival8. In the study aimed
to check whether the NHL patients have reduced IgA
level and that allergy or atopy is associated with a re-
duced risk of lymphoma10,14,19,29, it was reported that all
immunoglobulin class levels are decreased in NHL pa-
tients15. The greatest difference between patients with
NHL and controls was seen in IgG. Patients with B-cell
NHL had consistenly lower median IgG levels than con-
trols for all immunoglobulin types14,15.
Our patients have more often polyclonal hyperimmu-
noglobulinaemia than hypoimmunoglobulinaemia. In 29%
patients we found increased IgG concentration, and in
25% increased IgA concentration. The most frequent ab-
erration seen by other authors was high IgA concentra-
tion11. At clinical presentation, patients with lympho-
proliferative disorders tended to have higher levels of
IgM1,30, and IgG1.
In our study statistically significant association be-
tween histological type of NHL and total serum proteins
was found. Patients with aggressive type of lymphoma
had significantly more often lower serum protein concen-
tration. It is possible that the aggressive malignant dis-
ease infiltrates organs decreasing protein synthesis or it
enhances the protein loss and/or degradation. The same
results are obtained analyzing the statistical correlation
between histological type of NHL, and serum albumins.
The patients with aggressive type of lymphoma had more
often lower concentration of serum albumins. The expla-
nation for this finding may be the same as for the correla-
tion of type of NHL and total serum proteins.
In our study it was found statistically significant asso-
ciation between the histological type of lymphoma and
alpha2-protiens as well as between immunological type of
lymphoma and serum alpha2-protiens. In aggressive type
NHL patients it was found more often higher alpha2-pro-
tein concentration as well as in T-NHL. Alpha2-protien
fraction in protein electrophoresis consists of several
proteins that are acute phase reactants. Both type of
lymphoma have aggressive clinical course and may cause
higher alpha2-protein production. In the relevant litera-
ture we have not found similar analyses.
We have not found statistically significant association
between immunological type of lymphoma and total se-
rum proteins, as well as between immunological origin of
lymphoma and serum albumins. In other hand, it was
found statistically significant correlation between immu-
nological origin of lymphoma and serum IgA. Patients
with B-NHL have significant more often IgA concentra-
tion aberration than T-NHL patients. It was not found
correlation between histological type of lymphoma and
serum immunoglobulins. In one old article it was pub-
lished the correlation between histologic type of lym-
phoma and IgA level. The authors found higher concen-
tration of immunoglobulin G and A in patients with
diffuse in comparison with the patients with follicular
NHL according Rappaport’s classification3.
In our study correlation between immunoglobulin G
and M and immunologic origin of NHL was not noticed.
The statistical analysis of immunoglobulin level and his-
tological type of lymphoma did not show any correlation.
Conclusions
A number of statistical analyses showed a higher or
lower degree of statistical significance correlations. The-
se results give a description of system, but not the insight
into pathogenesis and manifestations of disease. It is nec-
essary to perform a prognostic analysis to assess clinical
reference of particular variable.
Over the last few years new immunoassays have
emerged that allow the measurement of free immuno-
globulin light chains in serum to a level of 2–4mg/L and
provide a much greater sensitivity than older methods,
such as immunofixation, which is able to detect free im-
munoglobulin light chains at a minimum concentration
of 100–150 mg/L25,31.
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SERUMSKI IMUNOGLOBULINI U BOLESNIKA SE NE-HODGKINOVIM LIMFOMOM
S A @ E T A K
Analizirali smo nalaze serumskih bjelan~evina i imunoglobulina (Ig) u 119 bolesnika sa ne-Hodgkinovim limfomom
(NHL). U 96 (81%) bolesnika dijagnosticiran je B-NHL, a u 23 (19%) T-NHL, mnogo ~e{}e indolentni tip (77 bolesnika,
65%), nego agresivni tip (42 bolesnika, 35%). U ve}ine bolesnika koncentracija serumskih bjelan~evina je bila u gra-
nicama normale. Povi{ena koncentracija serumskih bjelan~evina je na|ena u 17%, a sni`ena u 7% bolesnika. Hipo-
albuminemija je mnogo ~e{}a (43%) nego hiperalbuminemija (1%). Za razliku od serumskog albumina, niske razine
drugih proteinskih frakcija su vrlo rijetke (0.6% bolesnika ima sni`ene alfa1-, 4% bolesnika ima sni`ene alfa-2 i 3%
bolesnika ima sni`ene beta-globuline), a povi{ene znatno ~e{}e (23% alfa-1, 37% alfa-2 i 8% beta-globulini). Poliklo-
nalna hiperimunoglobulinemija je ~e{}a nego hipoimunoglobulinemija. U 29% boelsnika na|ena je povi{ena razina IgG
i u 25% bolesnika povi{ena razina IgA. Hipoimunoglobuinemija IgM (22%) je mnogo ~e{}a nego IgG (11%) i IgA (8%). U
11 (7%) bolesnika u elektroforezi serumskih bjelan~evina na|ena je monoklonalna gamapatija. Nije na|ena statisti~ki
zna~ajna povezanost izme|u koncentracije serumskih imunoglobulina i stupnja malignosti limfoma kao niti izme|u
koncentracije serumskih imunoglobulina i imunolo{kog porijekla limfoma. Bolesnici sa T-NHL imaju ~e{}e koncen-
traciju IgA iznad ili ispod normalnih vrijednosti nego bolesnici s B-NHL (p<0,05).
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